331.2 𩺠åèç
331.2.1 é«é »èé»
331.2.1.4 First-Line Pharmacotherapy
- Varenicline (partial agonist) â most effective
- NRT (patch + short-acting combination)
- Bupropion (NDRI)
331.2.1.5 Varenicline
- α4β2 nicotinic partial agonist
- 0.5 mg à 3d â 1 mg BID à 12 weeks
- Side effects: nausea, vivid dreams
- EAGLES trial: no excess neuropsychiatric risk
331.2.1.7 Bupropion
- NDRI
- Avoid if: seizure, eating disorder, alcohol withdrawal
- 150 mg daily à 3 d â 150 mg BID à 12 weeks
331.2.1.8 Cytisine
- Plant-derived α4β2 partial agonist
- Cheaper than varenicline
- FDA approval pending 2024-2025
331.2.1.9 Combination Therapy
- Pharmacotherapy + behavioral = best
- NRT patch + gum/lozenge: more effective than single
- Varenicline + NRT: synergistic, selected use
331.2.1.10 Behavioral Support
- CBT
- Motivational interviewing
- Telephone quitlines
- Text messaging
- Mobile apps
331.2.2 ææ··æ·æ¯èŒ
| Agent | Mechanism | Efficacy | Avoid If |
|---|---|---|---|
| Varenicline | α4β2 partial agonist | High (most effective single) | Severe psychiatric |
| NRT | Nicotine replacement | High (with combination) | Severe MI recent |
| Bupropion | NDRI | Moderate | Seizure, eating disorder |
| Cytisine | α4β2 partial agonist | Comparable to varenicline | Future FDA |
| Combination NRT | Two products | Higher than single | â |
| Varenicline + NRT | Combination | Synergistic | â |